Are Novavax’s protein technology Covid shots & omicron-fighting prototype worth Investing : Novavax, Inc. (NASDAQ: NVAX) ?
Novavax, Inc (NASDAQ: NVAX) is a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Prior to 2020, company developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases.